• WX20191112-100800
    Irwin Wang – CEO, Reistone Biopharma, China

    Dr Irwin Wang, CEO of Reistone Biopharma, shares her motivations behind the establishment of the company, their extremely productive collaboration with Jiangsu Hengrui (China’s largest pharma company by market capitalization), and their exciting international clinical development strategy for their three assets.

  • prn_cision_logo_desktop
    Reistone Announces First Patient Dosed in Two Phase II Global Studies of SHR0302 JAK Inhibitor for Ulcerative Colitis and Crohn’s Disease

    SHANGHAI, June 14, 2019 /PRNewswire/ -- Reistone Biopharma Company Limited (Reistone) announced today dosing of the first patient in their Phase II global clinical trials (RSJ10101 and RSJ10201) of SHR0302 in patients with Ulcerative Colitis and Crohn's disease respectively. The Phase II studies are randomized, double-blind, placebo-controlled, four arms parallel, multi-center Phase II study to investigate the safety and efficacy of SHR0302 in patients with moderate to severe active Ulcerative Colitis and Crohn's Disease.

  • 图片1
    Reistone Biopharma, a new Chinese biotech company ready to initiate its Ulcerative Colitis phase II clinical trial globally

    SHANGHAI, Oct. 22, 2018 /PRNewswire/ -- Reistone Biopharma Company Limited ( Reistone ), a clinical stage biopharmaceutical company headquartered in Shanghai, today announced the US FDA approval of IND for phase II clinical trial to investigate the efficacy and safety of selective Janus Kinase 1 inhibitor ( JAK1 ) in moderate to severe ulcerative colitis (UC) in the United States. The approval is a first step to enable the initiation of the clinical program in China, the United States and several European countries simultaneously.